Key facts
- It has raised $5.7M; the latest was Early Stage VC ($5.7M) in Aug 2025.
- Notable investors include SBI Investment, DEEPCORE, 77 Capital, D3 (Tokyo), Spurcle — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for RevolKa
- ·The full record, as it builds
Funding rounds
No funding rounds for RevolKa are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About RevolKa
Operator of a protein engineering platform intended to develop proteins by integrating evolutionary molecular biology with artificial intelligence. The company utilizes AI to predict and evolve protein sequences, enhancing multiple functions simultaneously to accelerate the development of high-performance proteins beyond natural evolutionary capabilities, enabling the therapeutics and vaccines industry to contribute to the health and well-being of people through assisted protein engineering technology.
- Sector
- Healthcare
- HQ
- Sendai, Japan
- Founded
- 2021
- Employees
- 11
- Website
- revolka.com/
- Ownership
- Privately Held (backing)
RevolKa doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in RevolKa shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on RevolKa in its N-PORT filings yet. We sweep new filings monthly.